Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
A modified gamma-cyclodextrin that binds to rocuronium or vecuronium, reversing its neuromuscular blocking action. Used intravenously.
Since the last update we have not found published data on its excretion in breast milk.
Side effects are rare and mild.
It is administered in single or isolated doses.
Its high molecular weight makes it unlikely that it will pass into milk in significant amounts.
Its low oral bioavailability would make it difficult its passage to the infant’s plasma through breast milk (EMA 2017).
Sugammadex can be used during breastfeeding (EMA 2017)